Phio Pharmaceuticals EBIT

The latest EBIT for PHIO is $-2.5M as of June 2026. That compares with $-3.9M in the prior-year period — up 35.8% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Phio Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, PHIO's EBIT moved from $-3.9M to $-2.5M — a 35.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Phio Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, PHIO currently prints $-2.5M for EBIT, while the sector average sits near $22B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Phio Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-2.5M for PHIO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting PHIO's EBIT ($-2.5M), review year-over-year change from $-3.9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.